Gyre Therapeutics Inc (GYRE) Dividendes

Gyre Therapeutics, Inc. operates as a biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 618 full-time employees. The company went IPO on 2006-04-12. The company is also advancing a diverse pipeline in the PRC through its controlling interest in Gyre Pharmaceuticals, including therapeutic expansions of ETUARY, and development programs for F573, and F528. F351 is a structural derivative of ETUARY. F573 is its clinical-stage product candidate for the treatment of acute/acute-on-chronic liver failure (ALF/ACLF) in Phase 2 clinical trials in the PRC. F528 is a preclinical-stage candidate targeting chronic obstructive pulmonary disease. The company is focused on commercializing therapies for the treatment of pulmonary fibrosis through its two therapeutic products: ETUARY (pirfenidone) and nintedanib. The company is also focused on commercializing the avatrombopag product and discovery and development of targeted protein degrader and degrader antibody conjugate therapies.